loading page

Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with covid-19: A randomized clinical trial
  • +7
  • Mohsen Sedighiyan,
  • Hamed Abdollahi,
  • Elmira Karimi,
  • Mostafa Badeli,
  • Reza Erfanian,
  • Shima Raeesi,
  • Rezvan Hashemi,
  • Zahra Vahabi,
  • Behzad Asanjarani,
Mohsen Sedighiyan

Corresponding Author:[email protected]

Author Profile
Hamed Abdollahi
Author Profile
Elmira Karimi
Tehran University of Medical Sciences
Author Profile
Mostafa Badeli
Author Profile
Reza Erfanian
Author Profile
Shima Raeesi
Author Profile
Rezvan Hashemi
Author Profile
Zahra Vahabi
Author Profile
Behzad Asanjarani
Author Profile
Author Profile


Objective: We hypothesized that omega-3 fatty acids would be an appropriate adjunct therapy for alleviating the inflammatory response and clinical manifestation in hospitalized patients with covid-19 disease. Methods: This was a single-blind randomized controlled trial in Amir-Alam hospital in Tehran. Thirty adult men and women diagnosed with covid-19 were allocated to either control group (receiving Hydroxychloroquine) or intervention group (receiving Hydroxychloroquine plus 2 grams of DHA+EPA) for 2 weeks. Primary outcome of the intervention including CRP, ESR as well as clinical symptoms including body pain, fatigue, appetite and olfactory and secondary outcomes including liver enzymes were determined at the baseline and after omega-3 supplementation. Clinical signs were measured using self-reported questionnaires. There were commercial kits for determination of CRP and liver enzymes concentrations in the serum of patients. For determination of ESR automated hematology analyzer was applied. Results: In comparison to control group, patients receiving omega-3 indicated favorable changes in all clinical symptoms except for olfactory ((p<0.001 for body pain and fatigue, p= 0.03 for appetite and p=0.21 for olfactory). Reducing effects of omega-3 supplementation compared to control group were also observed in the levels of ESR and CRP after treatment (p<0.001 for CRP and p=0.02 for ESR). However, no between group differences in the liver enzymes serum concentrations were observed after supplementation (p>0.05). Conclusion: Current observations are very promising and indicate that supplementation with moderate dosages of omega-3 fatty acids may be beneficial in the management of inflammation-mediated clinical symptoms in covid-19 patients. Key words: Covid-19, omega-3, inflammation, clinical symptoms
23 Dec 2020Submitted to International Journal of Clinical Practice
04 Jan 2021Submission Checks Completed
04 Jan 2021Assigned to Editor
13 Jan 2021Reviewer(s) Assigned
05 Feb 2021Review(s) Completed, Editorial Evaluation Pending
13 May 20211st Revision Received
22 Jul 2021Submission Checks Completed
22 Jul 2021Assigned to Editor
22 Jul 2021Review(s) Completed, Editorial Evaluation Pending
10 Sep 2021Editorial Decision: Accept
26 Sep 2021Published in International Journal of Clinical Practice. 10.1111/ijcp.14854